Merck Sheds $10 Billion as Bristol-Myers Study Dents Euphoria

(Bloomberg) -- Positive results from a late-stage study of Bristol-Myers Squibb Co.’s combination therapy for lung cancer dented some of investors’ euphoria about Merck & Co.’s Keytruda heading int...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.